Cambridge Biomedical In the News
NEOGENIX ONCOLOGY and CAMBRIDGE BIOMEDICAL form Partnership for Development of Blood based Cancer Diagnostic Tests
Rockville, MD (June 17, 2011) - Neogenix Oncology, Inc. is pleased to announce it has signed an agreement with Cambridge Biomedical, Inc, Boston, Mass. for the development of its pancreatic and colorectal cancer diagnostic serum ELISA assays. Cambridge Biomedical provides core expertise in assay optimization and validation within a CLIA certified and CAP accredited FDA recognized laboratory. Neogenix has developed tumor specific biomarkers for the detection of pancreatic and colorectal cancer in tissue and serum. The ELISA assay utilizes the Neogenix patent protected therapeutic monoclonal antibodies (Neo-101, NEO 201, NEO 301) . These diagnostic assays will serve as the companion products for the Neogenix anti-cancer mAb therapeutic pipeline and hold additional hope for early detection of pancreatic and colorectal cancer.
Philip M. Arlen, CEO and President of Neogenix Oncology said, "This represents a critical milestone for Neogenix as we aim to validate our Companion Diagnostic Biomarkers for performance within a CAP/CLIA laboratory environment. We are extremely excited about our partnership with Cambridge Biomedical which brings a fully integrated team in both assay development and serves as a nationally recognized clinical reference laboratory.
"Neogenix's therapeutic antibodies and companion diagnostic products are potentially significant steps towards the early detection and treatment of pancreatic and colorectal cancer. Cambridge Biomedical is proud to be able to apply its analytical and regulatory expertise to accelerate the commercialization process to make these much needed products available to afflicted patients.", said Dr. John J. Reddington, COO of Cambridge Biomedical Inc.
About Neogenix Oncology, Inc.
Neogenix Oncology is a clinical stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate, and other cancers. The company's portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. The company has its corporate headquarters and research and development laboratories in Rockville, MD and has a diagnostic laboratory in Great Neck, NY. The company is presently conducting a clinical study to establish certain of its antibodies as a serum diagnostic for pancreatic and colorectal cancers, and in December 2009 began a multicenter Phase I therapeutic trial to evaluate the clinical safety of the NPC-1C antibody in patients with metastatic pancreatic and colorectal cancer. For more information, visit www.neogenix.com.
About Cambridge Biomedical, Inc.
Cambridge Biomedical is a contract laboratory service organization that works with biotechnology, pharmaceutical and reference laboratories. The Company specializes in custom assay development, qualification and validation. Assays are performed in the company's CLIA / CAP accredited laboratory. Testing capabilities include clinical trial, diagnostic, and biosafety testing. Cambridge Biomedical's laboratories specialize in custom solutions for testing needs in support of Pre-clinical and Phase I-IV clinical trials. For more information, visit www.cambridgebiomedical.com
Forward Looking Statements
Certain statements contained in this release are forward-looking statements that relate to future events. These statements are based on current expectations only and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results express or implied by such forward-looking statements, including those risk factors discussed in the company's SEC reports, including the company's Form 10 and quarterly reports on Form 10-Q. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.